Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

930 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-01

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe malaria and bacterial Blood Stream Infections (bBSI) are impossible to differentiate clinically. This poses a particular threat in low resource areas, where bBSI is often not diagnosed due to the unavailability of rapid diagnostic means. Even if used appropriately, the sensitivity of blood culture to diagnose bBSI is estimated to be around 50%. To counter the high mortality rate associated with bBSI, antibiotics are often prescribed without microbiological confirmation. Sysmex Company has developed technology that enables the rapid diagnosis of malaria using a venous blood sample. In addition algorithms based on hematological parameters can be used to monitor disease severity and progression, as well as guide further diagnostic testing based on differences seen in these parameters between various types of disease. The algorithms have been developed and tested in adult populations from different industrialized countries and in one Asian population. However no data are available neither from pediatric patients, nor from the sub-Saharan setting where the epidemiology of infectious diseases is very different from the tested settings. The objective of the study is to: 1) Assess the sensitivity and specificity of the Sysmex hematology analyzer based on the new technology to diagnose malaria in subjects older than 3 months, who present with an acute severe febrile illness in a malaria endemic area in sub-Saharan Africa 2) Test and optimize the value of Sysmex analyzers in disease diagnosis and monitoring in children older than 5 years and adults, who present with an acute severe febrile illness in a malaria endemic region in sub-Saharan Africa, to differentiate between severe malaria and bBSI, or a combination of these infections. 3) Explore the value of Sysmex analyzers in disease diagnosis and monitoring in children between 3 months and 5 years of age, who present with an acute severe febrile illness in a malaria endemic region in sub-Saharan Africa.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection

NCT01002833

Plasmodium Falciparum Malaria

COMPLETED NA

Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires

NCT01214876

Malaria Schistosomiasis Hiv Infection

COMPLETED

Testing a Biometric Identification System to Improve Malaria Vaccine Completion

NCT07261280

Vaccination

RECRUITING NA

Yersinia Pestis Lateral Flow Immunoassay for Blood Samples

NCT04688996

Plague Plague, Bubonic Plague, Pneumonic +8 more

UNKNOWN

Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense)

NCT02672228

Malaria

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Analytical plan

Sysmex will be blinded to:

* All clinical data except age and gender of the participant
* All laboratory and imaging data that is not obtained by the XN-analyzers.

The clinical study team will be blinded to:

\- Data from the XN-analyzers, excepting the currently validated data that is used for routine patient care (e.g. total blood count, white blood differentiation)

Two researchers from Sysmex and two researchers from the study team will use the data available to them (i.e. the data to which they are not blinded) to categorize each patient according to the following categories (independently from each other) using the predefined case definitions as mentioned above.

1. Confirmed malaria parasitemia
2. Confirmed bacterial infection
3. Confirmed viral infection
4. Suspected malaria
5. Suspected bacterial infection
6. Suspected viral infection
7. Mixed infection (specified which combination)
8. No infection

Analysis for primary outcome measures

1. Diagnostic sensitivity and specificity of blue laser compared to microscopy/PCR
2. ROC curve to assess best cut-off for the blue laser based on clinical samples
3. Linear regression analysis to compare quantification of parasitemia by blue laser to microscopy/PCR
4. Compare performance of the blue laser to performance of RDT (in comparison to microscopy/PCR)
5. Diagnostic sensitivity and specificity of infection manager to detect bBSI in participants of 5 years and older.
6. Diagnostic sensitivity and specificity of the infection manager to detect bBSI combined with malaria in participants of 5 years and older.

Case definitions:

Malaria parasitemia is defined as the presence of one or more parasites in malaria microscopy or a malaria qPCR 18S result over 50 p/ml

Bacterial bloodstream infection is defined as growth of a clinically significant bacterial organism from blood culture within 5 days of incubation or a (16s) PCR result positive for a clinically significant organism

Lower respiratory tract infection: a clinical suspicion including cough and/or shortness of breath, supported by results from chest exam and chest X-ray.

Abscess: in case of superficial abscesses clinical presentation must be confirmed by pus upon drainage. In case of deep abscesses the clinical presentation must be confirmed by echography.

Meningitis: A clinical suspicion with decreased conscience and neck stiffness, confirmed by culture or agglutination performed on cerebrospinal fluid.

Pelvic inflammatory infection: Typical clinical presentation with vaginal discharge

Protrude skin infections: clinical presentation combined with a grown pathogen in skin culture or presence of pus.

Bacterial gastro-enteritis: Patients with diarrhoea and a grown pathogen from stool culture.

Urinary tract infections: Patients clinical signs of a urinary tract infection and a grown pathogen from urine culture.

Obvious causes of fever include superficial skin infection, superficial abscesses, otitis, pharyngitis and tonsillitis.

Viral infections will be diagnosed based on clinical suspicion and confirmed using PCR or serology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tropical Infectious Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children <15y

no intervention

None, treatment as actual best practice

Intervention Type OTHER

Adults >=15y

no intervention

None, treatment as actual best practice

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None, treatment as actual best practice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children between ages \>3 months and \< 15 years old OR adults of 15 years and above
2. AND willing and able to provide written informed consent (parent's or guardian's consent for minors). In case of very sick adults not able to give consent, sampling will be done and ICF will be asked upon his/her recovery or from his/her representative in case of death.
3. AND presenting with one of the following:

Recorded temperature of \> 38.0°C or temperature \< 35.5°C (tympanic). OR episode of fever within 48 hours prior to admission

OR signs of severe clinical illness including one or more of the following:
* Respiratory distress
* Prostration
* Altered consciousness
* Convulsions (one or more episodes)
* Clinical jaundice
* Signs of shock
* Severe malnutrition with severe anemia (hemoglobin \< 5 g/dl)
4. AND Having one of the following clinically suspected infections

* Severe malaria
* Invasive bacterial infection (including pneumonia, arthritis, peritonitis, meningitis or complicated urinary tract infection, typhoid fever)
* Severe viral infection such as influenza